Rhythm Pharmaceuticals (RYTM) Stock Price, News & Analysis

Company Overview

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare genetic diseases of obesity and related metabolic disorders. The company’s research is centered on the melanocortin-4 receptor (MC4R) pathway, which plays an important role in regulating hunger and energy balance.

Rhythm’s primary product is IMCIVREE (setmelanotide), an MC4R agonist. In the United States, IMCIVREE is approved for chronic weight management in adults and children at least 2 years old with obesity and certain genetically confirmed conditions affecting the MC4R pathway, including pro-opiomelanocortin, proprotein convertase subtilisin/kexin type 1 and leptin receptor deficiencies, as well as Bardet-Biedl syndrome. The company is also advancing research intended to expand treatment options for additional rare metabolic diseases.

Rhythm was founded in 2008 and is headquartered in Boston, Massachusetts. Its commercial and development activities primarily serve patients in the United States and other international markets where IMCIVREE has received regulatory authorization. David R. Meeker has served as the company’s chief executive officer and chairman.

Key Stats

• Today's Range: $96.47 to $100.02
• 50-Day Range: $96.77 to $117.60
• 52-Week Range: $74.50 to $122.20
• Volume: 439,196 shs
• Average Volume: 753,699 shs
• Market Capitalization: $6.73 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $140.67
• Consensus Rating: Moderate Buy

Rhythm Pharmaceuticals Stock Analysis - MarketRank™

Rhythm Pharmaceuticals scored higher than 56% of companies evaluated by MarketBeat, and ranked 385th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Rhythm Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.76, and is based on no strong buy ratings, 17 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Rhythm Pharmaceuticals has a consensus price target of $140.67, representing about 44.5% upside from its current price of $97.33.

Amount of Analyst Coverage

Rhythm Pharmaceuticals has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Rhythm Pharmaceuticals are expected to grow in the coming year, from ($2.86) to ($0.43) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rhythm Pharmaceuticals is -31.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rhythm Pharmaceuticals is -31.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rhythm Pharmaceuticals has a P/B Ratio of 46.79. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

15.98% of the float of Rhythm Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Rhythm Pharmaceuticals has a short interest ratio ("days to cover") of 21.89, which indicates bearish sentiment.

Change versus previous month

Short interest in Rhythm Pharmaceuticals has recently increased by 1.46%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rhythm Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Rhythm Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.45

News Sentiment

Rhythm Pharmaceuticals has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Rhythm Pharmaceuticals this week, compared to 6 articles on an average week.

Search Interest

2 people have searched for RYTM on MarketBeat in the last 30 days.

MarketBeat Follows

3 people have added Rhythm Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Rhythm Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,796,497.00 in company stock.

Percentage Held by Insiders

5.90% of the stock of Rhythm Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Rhythm Pharmaceuticals has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 9/23/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RYTM
• CIK: 1649904
• Web: www.rhythmtx.com
• Phone: (857) 264-4280
• Fax: 857-264-4299
• Employees: 414
• Year Founded: 2008

Price Target and Rating

• Average Price Target for Rhythm Pharmaceuticals: $140.67
• High Price Target: $160.00
• Low Price Target: $100.00
• Potential Upside/Downside: +43.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.76
• Research Coverage: 21 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.11)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$196.54 million
• Net Margins: -85.59%
• Pretax Margin: -85.14%
• Return on Equity: -159.87%
• Return on Assets: -44.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.45
• Quick Ratio: 3.20

Sales & Book Value

• Annual Sales: $189.76 million
• Price / Sales: 35.45
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.08 per share
• Price / Book: 47.20

Miscellaneous

• Outstanding Shares: 68,530,000
• Free Float: 64,490,000
• Market Cap: $6.73 billion
• Optionable: Optionable
• Beta: 1.97